Jubilant Pharmova and Sun Pharma Approve Fundraising via Non-Convertible Debentures
Jubilant Pharmova and Sun Pharmaceutical Industries have both approved plans to raise funds through the issuance of non-convertible debentures (NCDs). Jubilant Pharmova's board approved up to Rs 800 crore in NCDs, while Sun Pharma's board approved up to Rs 10,000 crore via private placement in one or more tranches. Both companies plan to list the debentures and comply with regulatory requirements. Additionally, Sun Pharma announced the resignation of independent director Gautam Doshi for personal reasons.
First-hand measurement across 3 sources
We measured how 3 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is neutral (50/100). Lens Score 34/100.
Outlets measured: businessstandard, news18, news18. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (50–50/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
news18 broke this story on 12 Oct, 05:45 pm. Other outlets followed.